IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`AMNEAL PHARMACEUTICALS LLC AND
`
`AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,
`Petitioners,
`
`ALLERGAN, INC.,
`Patent Owner.
`
`Case No. IPR2018-00608
`
`Patent No. 9,161,926
`
`POWER OF ATTORNEY FROM PATENT OWNER ALLERGAN, INC.
`
`

`

`IPR2018-00608
`
`Pursuant to 37 CPR. § 42.10(b), Patent Owner Allergan, Inc. hereby appoints
`
`the following lead and back-up counsel as its attorneys to transact all business in the
`
`United States Patent and Trademark Office associated with the above-captioned
`
`Inter Partes Review.
`
`A Statement Under 37 C.F.R. § 3.73(c) is submitted herewith.
`
`Lead Counsel
`
`Back-Us Counsel
`
`Jessica L. Parezo (Reg. No. 50,286)
`Scott E. Kamholz (Reg. No. 48,543)
`
`jparezo@cov.com
`skamholz@cov.com
`
`Postal and Hand-Deliveg Address:
`Postal and Hand-Deliveg Address:
`
`Covington & Burling LLP
`Covington & Burling LLP
`
`One CityCenter, 850 Tenth Street, NW One CityCenter, 850 Tenth Street, NW
`
`Washington, DC 20001
`Washington, DC 20001
`
`Phone: (202) 662—5339
`Phone: (202) 662-5498
`Fax: (202) 778-5339
`Fax: (202) 778-5498
`
`
`
`
`
`
`
`
`
`
`The individual signing below has the authority to execute this document on
`
`behalf of Patent Owner Allergan, Inc.
`
`Date; 9k. 11‘ 20‘? £ 2 KW
`
`Name: Thomas F. Poché, Ph.D.
`Title: Vice President and Assist. General Counsel
`
`Intellectual Property Management & Strategy
`
`

`

`PTO/AIA/96 (08-12)
`Approved for use through 01/31/2013. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Pa erwork Reduction Act of 1995, no -ersons are re- uired to res- -nd to a collection of information unless it dis -la
`a valid OMB control number.
`
`STATEMENT UNDER 37 CFR 3.73(c)
`
`Applicant/Patent Owner:
`
`Allergan, Inc.
`
`October 20, 2015
`Filed/Issue Date:
`9,161,926
`Application No./Patent No.:
`Titled:
`TOPICAL DAPSONE AND DAPSONE/ADAPLENE COMPOSITIONS AND METHODS FOR USE
`THEREOF
`
`(Name of Assignee)
`
`Allergan, Inc.
`
`, a
`
`Corporation
`(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
`
`states that, for the patent application/patent identified above, it is (choose % of options 1, 2, 3 or 4 below):
`
`The assignee of the entire right, title, and interest.
`
`2. [:1 An assignee of less than the entire right, title, and interest (check applicable box):
`D The extent (by percentage) of its ownership interest is
`%). Additional Statement(s) by the owners
`holding the balance of the interest must be submitted to account for 100% of the ownership interest.
`
`There are unspecified percentages of ownership. The other parties, including inventors, who together own the entire
`right, title and interest are:
`
`Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the
`entire right, title, and interest.
`
`3. D The assignee of an undivided interest in the entirety (a complete assignment from one of the joint inventors was made).
`The other parties, including inventors, who together own the entire right, title, and interest are:
`
`
`
`Additional Statement(s) by the owner(s) holding the balance of the interest must be submitted to account for the
`entire right, title, and interest.
`
`4- CI The recipient, via a court proceeding or the like (e.g., bankruptcy, probate), of an undivided interest in the entirety (a
`complete transfer of ownership interest was made). The certified document(s) showing the transfer is attached.
`
`The interest identified in option 1, 2 or 3 above (not option 4) is evidenced by either (choose 91E of options A or B below):
`A. D An assignment from the inventor(s) of the patent application/patent identified above. The assignment was
`recorded in the United States Patent and Trademark Office at Reel
`,
`Frame
`, or for which a copy thereof is attached.
`
`A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
`
`Allergan, Inc.
`To:
`Inventors Warner & Parashar
`1. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`033479
`
`, Frame
`
`0112
`
`, or for which a copy thereof is attached.
`
`Allergan, Inc.
`To:
`Dow Pharmaceutical Sciences
`2. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`033479
`
`, Frame
`
`0992
`
`, or for which a copy thereof is attached.
`
`[Page 1 of 2]
`
`

`

`PTO/AIA/QG (08-12)
`Approved for use through 01/31/2013. OMB 0651-0031
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`STATEMENT UNDER 37 CFR 3.73lc)
`
`Dow Pharmaceutical Sciences
`To:
`Inventors Bhatt & Swaminathan
`3. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`033479
`
`, Frame
`
`0214
`
`, or for which a copy thereof is attached.
`
`Allergan, Inc.
`To:
`Inventors Parashar &Warner
`4. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`038397
`
`, Frame
`
`0716
`
`, or for which a copy thereof is attached.
`
`Dow Pharmaceutical Sciences
`To:
`Inventors Bhatt & Swaminathan
`5. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`038397
`
`, Frame
`
`0761
`
`, or for which a copy thereof is attached.
`
`Allergan, Inc.
`To:
`Dow Pharmaceutical Sciences
`6. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`038397
`
`, Frame
`
`0799
`
`, or for which a copy thereof is attached.
`
`[3 Additional documents in the chain of title are listed on a supplemental sheet(s).
`
`As required by 37 CFR 3.73(c)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee
`was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
`
`[NOTE: A separate copy (Le, a the copy of the original assignment document(s)) must be submitted to Assignment Division
`in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
`
`The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
`
`Title or Registration Number
`
`Mime—BLAH?“
`
`Signature
`
`Date
`
`Thomas F. Poché, Ph.D.
`Printed or Typed Name
`
`Vice President and Assist. General Counsel
`
`Intellectual Property Management & Strategy
`
`[Page 2 of 2]
`
`

`

`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CPR. § 42.6, I hereby certify that the foregoing Power of
`
`Attorney from Patent Owner Allergan, Inc. and accompanying Statement Under 37
`
`CFR 3.73(c) were served by electronic mail on the following counsel of record for
`
`petitioner.
`
`Dennies Varughese (dvarughe—PTAB@skgf.com)
`Adam C. LaRock (alarock-PTAB@skgf.com)
`PTAB@skgf.com
`Sterne, Kessler, Goldstein & Fox
`1100 New York Avenue, NW
`Washington, DC 20005
`
`Date: February 28 2018
`
`/Scott E. Kamholz, Reg. No. 48,543/
`Scott E. Kamholz
`
`Registration No.: 48,543
`
`